Susceptibility of bacterial isolates to β-lactam antibiotics from U.S. clinical trials over a 5-year period
- 24 June 1996
- journal article
- research article
- Published by Elsevier in The American Journal of Medicine
- Vol. 100 (6) , 13S-19S
- https://doi.org/10.1016/s0002-9343(96)00103-9
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- In vitro activity of E-1040, a novel cephalosporin with potent activity against Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 1988
- In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7620 consecutive clinical bacterial isolatesDiagnostic Microbiology and Infectious Disease, 1986
- The activity of BMY 28142 a new broad spectrum β-lactamase stable cephalosporinJournal of Antimicrobial Chemotherapy, 1986
- Antibacterial activity of BMY-28142, a novel broad-spectrum cephalosporin.The Journal of Antibiotics, 1986
- In-vitro activity of BMY 28142, a new aminothiazolyl cephalosporinJournal of Antimicrobial Chemotherapy, 1985
- Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporinAntimicrobial Agents and Chemotherapy, 1985
- In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agentsAntimicrobial Agents and Chemotherapy, 1985
- HR 810 and BMY-28142, two new cephalosporins with broad-spectrum activity:an in-vitro comparison with other β-lactam antibioticsJournal of Antimicrobial Chemotherapy, 1985
- In vitro studies of BMY-28142, a new broad-spectrum cephalosporinAntimicrobial Agents and Chemotherapy, 1985
- Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibioticsAntimicrobial Agents and Chemotherapy, 1985